Nexus Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEXUS PHARMS, and what generic alternatives to NEXUS PHARMS drugs are available?
NEXUS PHARMS has fourteen approved drugs.
There are two US patents protecting NEXUS PHARMS drugs.
There are seven patent family members on NEXUS PHARMS drugs in seven countries and seventy-one supplementary protection certificates in eight countries.
Drugs and US Patents for Nexus Pharms
International Patents for Nexus Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3968975 | See Plans and Pricing |
Israel | 288044 | See Plans and Pricing |
Australia | 2020276619 | See Plans and Pricing |
South Korea | 20220009985 | See Plans and Pricing |
China | 113825500 | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 2020232424 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nexus Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0480717 | 98C0022 | France | See Plans and Pricing | PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825 |
1441735 | SPC/GB08/020 | United Kingdom | See Plans and Pricing | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
0480717 | SPC/GB98/025 | United Kingdom | See Plans and Pricing | PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115 |
0145340 | 99C0005 | Belgium | See Plans and Pricing | PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204 |
2203431 | 15C0013 | France | See Plans and Pricing | PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119 |
2932970 | SPC/GB18/041 | United Kingdom | See Plans and Pricing | PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.